Are new antibiotics in therapy of respiratory tract infections necessary?

Increasing worldwide antibacterial resistance among respiratory pathogens, especially S. pneumoniae, are an emerging problem in the treatment of respiratory tract infections. In some areas penicillin-resistant S. pneumoniae increased to 80% and macrolide-resistance and MLSb-resistance are an evolvin...

Full description

Saved in:
Bibliographic Details
Published in:Wiener medizinische Wochenschrift 2003, Vol.153 (15-16), p.345
Main Authors: Haberl, Renate, Wenisch, Christoph, Domej, Wolfgang
Format: Article
Language:ger
Subjects:
Anti-Bacterial Agents - adverse effects
Anti-Bacterial Agents - therapeutic use
Bacterial Infections - drug therapy
Bacterial Infections - microbiology
Drug Resistance, Multiple
Drugs, Investigational - adverse effects
Drugs, Investigational - therapeutic use
Humans
Penicillin Resistance
Pneumococcal Infections - drug therapy
Pneumococcal Infections - microbiology
Respiratory Tract Infections - drug therapy
Respiratory Tract Infections - microbiology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Increasing worldwide antibacterial resistance among respiratory pathogens, especially S. pneumoniae, are an emerging problem in the treatment of respiratory tract infections. In some areas penicillin-resistant S. pneumoniae increased to 80% and macrolide-resistance and MLSb-resistance are an evolving problem. In addition, increasing resistance to quinolones has been documented in Hong Kong and in Spain. One way to combat increasing resistance is the development of new antimicrobial drugs. However, the practice of just changing one drug for another without also altering poor prescribing habits merely results in different resistance issues. In the long-term, to prevent increasing resistance, clinicians must be aware of restrictive antibiotic prescription and adequate dosages.
ISSN:0043-5341
1563-258X